- Home
- WSBK vs GALT Comparison
WSBK vs GALT Comparison
Compare WSBK & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WSBK
- GALT
- Stock Information
- Founded
- WSBK 2024
- GALT 2000
- Country
- WSBK United States
- GALT United States
- Employees
- WSBK N/A
- GALT N/A
- Industry
- WSBK
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- WSBK
- GALT Health Care
- Exchange
- WSBK NYSE
- GALT Nasdaq
- Market Cap
- WSBK 83.8M
- GALT 83.5M
- IPO Year
- WSBK N/A
- GALT N/A
- Fundamental
- Price
- WSBK $9.50
- GALT $2.52
- Analyst Decision
- WSBK
- GALT Buy
- Analyst Count
- WSBK 0
- GALT 2
- Target Price
- WSBK N/A
- GALT $6.00
- AVG Volume (30 Days)
- WSBK 18.5K
- GALT 1.5M
- Earning Date
- WSBK 01-01-0001
- GALT 08-12-2025
- Dividend Yield
- WSBK N/A
- GALT N/A
- EPS Growth
- WSBK N/A
- GALT N/A
- EPS
- WSBK 0.02
- GALT N/A
- Revenue
- WSBK $15,687,000.00
- GALT N/A
- Revenue This Year
- WSBK N/A
- GALT N/A
- Revenue Next Year
- WSBK N/A
- GALT N/A
- P/E Ratio
- WSBK $567.38
- GALT N/A
- Revenue Growth
- WSBK N/A
- GALT N/A
- 52 Week Low
- WSBK $8.76
- GALT $0.73
- 52 Week High
- WSBK $10.10
- GALT $3.90
- Technical
- Relative Strength Index (RSI)
- WSBK N/A
- GALT 63.30
- Support Level
- WSBK N/A
- GALT $2.07
- Resistance Level
- WSBK N/A
- GALT $2.36
- Average True Range (ATR)
- WSBK 0.00
- GALT 0.27
- MACD
- WSBK 0.00
- GALT -0.01
- Stochastic Oscillator
- WSBK 0.00
- GALT 61.64
About WSBK WINCHESTER BANCORP INC
Winchester Bancorp Inc provides a variety of financial services to individuals and small businesses through its offices in Winchester, Woburn, Danvers and Arlington, Massachusetts. Its primary deposit products are checking, savings and term certificate accounts and its primary lending products are residential and commercial real estate loans.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.